Pharma Pulse: FDA Approval of Icotyde for Plaque Psoriasis and CCT’s MedAssure Debut

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.

• Cold Chain Technologies (CCT) will debut its MedAssure orchestration platform at LogiPharma 2026. According to CCT, MedAssure provides proactive, data-driven intelligence to optimize cold chain performance. Beyond reducing logistics costs, the platform is engineered to support industry decarbonization goals by minimizing the environmental burden of wasted products.
• In other news, The FDA has approved Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque psoriasis in adults and adolescents. This once-daily pill blocks the IL-23 receptor, offering a systemic treatment option that avoids the injection-based administration typical of other IL-23 biologics. In superiority studies, approximately 70% of patients achieved clear or almost clear skin at week 16.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.